EMA Authorised: Kovaltry (octocog alfa) — Bayer AG

View source ↗

Summary

The EMA authorised Kovaltry (octocog alfa) from Bayer AG for the treatment of Hemophilia A. Decision date: 13 August 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Kovaltry (octocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Bayer AG. Decision date: 13/08/2025